



1FW

Docket No.: REG 990A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: GLASS ET AL.

Serial No.: 10/768,932

Group: to be assigned


Filing Date: 30 January 2004


Examiner: to be assigned

Title: HIV-SPECIFIC FUSION PROTEINS AND THERAPEUTIC AND
DIAGNOSTIC METHODS FOR USE

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.


Loren Hernandez


Date

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450.

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Fees

No fee is required for the filing of this Information Disclosure Statement. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted



Valeta Gregg
Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400

FORM PTO-1449



Att. Docket No. REG 990A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 990A
Serial No. : 10/768,932
Applicant: : Glass et al.
Date Filed : 30 January 2004
For : HIV-Specific Fusion Proteins and
Therapeutic and Diagnostic Methods for
Use
Examiner : Not Yet Known
Group Art Unit : Not Yet Known

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner</u> <u>Initials</u>	<u>Patent</u> <u>Number</u>	<u>Patent</u> <u>Date</u>	<u>Name</u>	<u>Class/</u> <u>Subclass</u>	<u>Filing</u> <u>Date</u>
------------------------------------	--------------------------------	------------------------------	-------------	----------------------------------	------------------------------

FOREIGN PATENT DOCUMENTS

<u>Examiner</u> <u>Initials</u>	<u>Document</u> <u>Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/</u> <u>Subclass</u>	<u>Translation</u> <u>Yes</u> <u>No</u>
------------------------------------	----------------------------------	-------------	----------------	----------------------------------	--

OTHER DOCUMENTS
(Including Author, title, Date, Pertinent Pages, etc.)

**Examiner
Initials**


_____ Klasse et al. (1999) Journal of Virology, 73:7453-7466

EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By: 
Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400